Please use this identifier to cite or link to this item:
Title: Clinically used selective oestrogen receptor modulators increase LDL receptor activity in primary human lymphocytes.
Issue Date: Mar-2015
Citation: Br. J. Pharmacol..2015 Mar;(172)5:1379-94
Abstract: Treatment with selective oestrogen receptor modulators (SERMs) reduces low-density lipoprotein (LDL) cholesterol levels. We assessed the effect of tamoxifen, raloxifene and toremifene and their combinations with lovastatin on LDL receptor activity in lymphocytes from normolipidaemic and familial hypercholesterolaemic (FH) subjects, and human HepG2 hepatocytes and MOLT-4 lymphoblasts.
PMID: 25395200
Rights: openAccess
Appears in Collections:Fundaciones e Institutos de Investigación > IIS H. U. Ramón y Cajal > Artículos

Files in This Item:
File Description SizeFormat 
PMC4337708.pdf1.1 MBAdobe PDFThumbnail

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.